IVF Add-Ons Reviewed: PGT-A, ERA & Assisted Hatching — What Evidence Supports

The IVF add-on menu is where hope meets retail. Time-lapse imaging, assisted hatching, endometrial receptivity testing, embryo glue, immune therapies, PGT-A — each priced in the hundreds to thousands, each pitched, with impeccable timing, at patients maximally motivated to buy anything that might plausibly help. The uncomfortable evidence-based summary: most add-ons have not demonstrated live-birth improvement in quality trials for general populations, several have been formally rated as unsupported by the UK regulator's review system, and a few have narrow, real indications buried under broad, profitable marketing. The honest shopping guide — what the regulators rated, what the trials found, what narrow indications survive scrutiny, and the single question that sorts the entire menu at any clinic on earth:

The Framework Before the Menu

Two principles sort everything. First, the outcome that counts is live birth — not fertilization rate, not embryo appearance, not implantation biomarkers. Add-ons routinely demonstrate effects on intermediate measures that never translate to more babies, and intermediate-endpoint marketing is the industry's signature move. Second, subgroup honesty: an intervention useless for general populations can be genuinely valuable for a specific indication — the question is never "does X work" but "does X improve live birth for patients like me," and the phrase "for patients like me" is the most powerful consumer tool in fertility medicine. The UK's HFEA maintains a public evidence-rating system for add-ons precisely because the market failed to self-regulate; its ratings — most common add-ons rate as unproven or without live-birth support for general use — are free, current, and worth reading before any checkout page.

The Menu, Item by Item

PGT-A (chromosomal screening, $3,000–6,000 US; $1,000–2,500 abroad). The biggest-ticket and most contested item — biopsying embryos to screen for chromosomal abnormalities. The headline randomized trial (STAR) found no overall live-birth improvement in general populations; plausible benefit narrows to older patients and specific histories via fewer failed transfers and possibly fewer miscarriages, not more babies per retrieval. It's consequential enough that it gets its own full both-sides treatment in our PGT-A debate piece — and per this site's standing scope, PGT discussion here means screening for chromosomal abnormalities and serious genetic disease, nothing else. ERA — endometrial receptivity testing ($800–1,500). The theory (find your personal implantation window) was elegant; the recent randomized evidence found no live-birth benefit in general populations, and routine ERA has moved from promising to largely unsupported. Fair residual use: selected repeated-implantation-failure cases, as a considered physician decision rather than a menu default. Assisted hatching ($400–1,000). Lasering a gap in the embryo's shell to ease hatching — decades old, repeatedly reviewed, and not recommended for routine use by professional guidance; narrow arguments persist for specific embryo characteristics. Time-lapse incubation ($500–1,500). Continuous embryo imaging without removal from the incubator — genuinely useful laboratory workflow technology whose selection algorithms have not shown live-birth improvement in trials; paying premium prices for it as an outcome-booster is buying a nicer camera, not a better baby chance. Embryo glue ($200–500), immune therapies (highly variable), endometrial scratch (~$300–500): the scratch was retired by a major trial showing no benefit; adherence compounds show no convincing live-birth effect; and empirical immune treatments for implantation failure remain unsupported by quality evidence and carry real side-effect profiles — the strongest professional guidance reserves them for research settings.

The Add-Ons That Aren't Framed as Add-Ons

Three purchases escape the add-on frame while behaving exactly like it. ICSI for non-male-factor is the biggest: charged at $1,000–2,500 as a line item, applied at rates far above male-factor prevalence at many clinics, and unsupported by evidence for improving live birth where sperm parameters are normal — the full case lives in our ICSI guide, and "we do ICSI on everything" is a lab-workflow statement wearing a medical costume. Extended culture and grading tiers — day-6/7 culture, AI-scored grading reports — bundle real lab practice with premium framing; the practice is legitimate, the premium's outcome effect is not established, and the question is what you're paying versus what changes. Freeze-all as a default upsell deserves nuance: clinically indicated freeze-all (high responders, OHSS risk, PGT logistics) is modern medicine; universal freeze-all pricing that adds a frozen-transfer fee to every patient regardless of indication is a business model — the distinction our frozen-vs-fresh piece equips you to draw at your own consult.

The meta-skill across all of them: ask what the default is and what changes it. Evidence-based programs have defaults (conventional insemination unless male factor; fresh transfer unless indication; no routine biopsy) and articulate exceptions; menu-driven programs have prices and enthusiasm. Five minutes of default-interrogation at a consult reveals which one you're sitting in more reliably than any review site.

Reading an Add-On Study Like a Skeptic

Three checks turn any add-on's cited study from authority into information. Endpoint: does the paper report live birth, or an intermediate proxy (implantation rate, embryo score, biomarker) that historically fails to translate? Population: was benefit shown in patients like you, or in a narrow subgroup the marketing then generalized — the reverse of subgroup honesty? Design: randomized trials outrank the observational studies that dominate add-on literature, where the patients who bought extras differ systematically from those who didn't (richer, often younger, better-prognosis — a bias that manufactures apparent benefits). A clinic citing "studies show" survives these three questions or it doesn't; most add-on pitches don't, which is the entire point of asking.

Why Clinics Sell What Evidence Doesn't Support

Not (usually) cynicism — a mix of genuine clinical belief, patient demand ("the last clinic offered it — why don't you?"), defensive medicine, and margin. Add-ons are high-profit lines in a competitive market, and patient psychology does the rest: after a failed cycle, "we'll add three things" feels like action, and declining an offered add-on feels like leaving a chance on the table. The corrective isn't cynicism either — it's the structured question: "What is the live-birth evidence for this in patients with my age and history, and would you recommend it if it were free?" Physicians practicing evidence-based medicine answer it comfortably, cite the trial or the regulator rating, and sometimes still recommend selectively — which is entirely legitimate; menus, defaults, and enthusiasm untethered from data are what the question disarms. Abroad, the same menu appears at lower prices (the arithmetic our live PGT-abroad guide covers for testing specifically), and cheaper unproven is still unproven — though it's fair to note the sting of a $1,200 gamble differs from a $6,000 one.

One caveat in the other direction, for fairness: evidence evolves, and today's unproven is occasionally tomorrow's standard — freeze-all for high responders made that journey inside a decade. The distinction worth holding is between clinics running research protocols transparently (consent forms, no-charge or cost-price participation, honest uncertainty) and clinics retailing uncertainty at margin. The first advances the field; the second bills it.

The Bottom Line

Spend where evidence lives: on the fundamentals that actually move outcomes — appropriate protocol, laboratory quality, single-blastocyst transfer strategy, and enough budget for a second cycle, which beats any add-on's effect size by an order of magnitude. Treat the add-on menu as a set of specific tools with narrow indications, ask the for-patients-like-me question every time, check HFEA's public ratings as a neutral reference, and let the PGT-A debate and frozen-vs-fresh evidence pieces carry the two decisions big enough to deserve their own files. The most valuable add-on in IVF remains the one nobody sells: another attempt — funded, as often as not, by every unproven line item you declined along the way.